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Background: Cyclooxygenase-2 (COX-2) is up-regulated in several types of cancer, and it is hypothesized that
COX-2 expression may be genetically influenced. Here, we evaluate the association between single-nucleotide
polymorphisms (SNPs) in the COX-2 gene (PTGS2) and the occurrence of breast cancer among Brazilian women.
Methods: The study was conducted prospectively in two steps: First, we screened the promoter region and three
fragments of the 3’-untranslated region of PTGS2 from 67 healthy Brazilians to identify SNPs and to select those
with a minor allele frequency (MAF) of at least 0.10. The MAF of these selected SNPs was further characterized in
402 healthy volunteers to evaluate potential differences related to heterogeneous racial admixture and to estimate
the existence of linkage disequilibrium among the SNPs. The second step was a case-control study with 318
patients and 273 controls designed to evaluate PTGS2 genotype- or haplotype-associated risk of breast cancer.
Results: The screening analysis indicated nine SNPs with the following MAFs: rs689465 (0.22), rs689466 (0.15),
rs20415 (0.007), rs20417 (0.32), rs20419 (0.015), rs5270 (0.02), rs20424 (0.007), rs5275 (0.22) and rs4648298 (0.01). The
SNPs rs689465, rs689466, rs20417 and rs5275 were further studied: Their genotypic distributions followed Hardy-
Weinberg equilibrium and the MAFs were not affected by gender or skin color. Strong linkage disequilibrium was
detected for rs689465, rs20417 and rs5275 in the three possible pairwise combinations. In the case-control study,
there was a significant increase of rs5275TC heterozygotes in cases compared to controls (OR = 1.44, 95%
CI = 1.01-2.06; P = 0.043), and the haplotype formed by rs689465G, rs689466A, rs20417G and rs5275C was only
detected in cases. The apparent association with breast cancer was not confirmed for rs5275CC homozygotes or
for the most frequent rs5275C-containing haplotypes.
Conclusions: Our results indicate no strong association between the four most frequent PTGS2 SNPs and the risk
of breast cancer.
Background
Cyclooxygenases (COXs) are key enzymes in mediating
the conversion of free arachidonic acid into prostaglan-
din H2, the precursor of molecules such as prostaglan-
dins, prostacyclin and thromboxanes [1]. Two isoforms
of cyclooxygenase (COX-1 and COX-2) are known. The
constitutive cyclooxygenase (COX-1) is present in many
tissues and synthesizes prostaglandins involved in main-
taining normal tissue homeostasis [2]. The inflammatory
enzyme COX-2 is not detected in most normal tissues
but can be induced by cytokines, growth factors or
tumor promoters. COX-2 catalyzes the synthesis of
prostaglandins, such as prostaglandin E2 (PGE2), which
can affect cell proliferation, apoptosis and angiogenesis
[3], contributing to tumor progression. COX-2 is pre-
sent in several types of solid tumors and, in breast can-
cer, is associated with parameters of aggressiveness,
including tumor size, positive nodal status and lower
survival [4,5]. In addition, inhibition of COX-2 by non-
steroidal anti-inflammatory drugs has been associated
with a protective effect against a variety of cancers [6]
and may be effective in the prevention and treatment of
breast cancer [7,8].
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expression remain unclear and may be influenced by
genetic variations. The human COX-2 gene, PTGS2,i s
located on chromosome 1 (locus q25.2-q25.3), is 8.3 kb
in size, contains 10 exons and produces an mRNA of
4.6 kb. The analysis of the promoter region (PR) reveals
the existence of several potential regulatory elements,
including a TATA box and transcription binding sites
for NF-kB, NF-IL6, AP-1, AP-2, GAS, TBP and cAMP
response element. Several genetic variants have been
described in regions next to these regulatory sites that
may affect enzyme expression [9,10] and contribute to a
greater risk of developing cancer.
In addition to variations in the PR, sites in the 3’-
untranslated region (3’-UTR) of the gene may also be
associated with increased risk of developing cancer. The
3’-UTR of the PTGS2 gene contains 30 AUUUA ele-
ments. Such repetitions generate consensus binding
sequences for proteins and inflammatory mediators that
regulate the stability and degradation of mRNA [11-13].
These repeats are also present in other genes encoding
inflammatory mediators (cytokines and proto-onco-
genes) whose mRNAs are very unstable [14]. Genetic
variations in the 3’-UTR of the PTGS2 gene may contri-
bute to increased stability of mRNA and the synthesis of
COX-2.
The frequency of SNPs in the PTGS2 gene may vary
between different ethnic groups [15,16]. No data are
available on the frequency of such variant forms in the
Brazilian population, either in healthy subjects or in
cancer patients. The high rate of racial admixture, with
a major contribution from Europeans and Africans in
the formation of the Brazilian population, suggests that
the variant forms of the PTGS2 g e n em a yh a v eah i g h
prevalence in Brazil and that their occurrence may lead
to haplotypes with different potentials for changes in
COX-2 expression.
In the present study, we identified single-nucleotide
polymorphisms (SNPs) in the PR and 3’-UTR of the
PTGS2 gene and evaluated their association with breast
cancer occurrence among Brazilians.
Methods
Experimental Design and Study Population
This study was conducted prospectively in two steps:
first, we screened 1.5 kb of the PR and three fragments
comprising 1.2 kb of the 3’-UTR of the PTGS2 gene in
67 healthy Brazilians to identify PTGS2 SNPs and to
select those with a minor allele frequency (MAF) of at
least 0.10. The frequency of these selected SNPs was
further characterized in 355 other healthy volunteers
(comprising a total of 402) to evaluate potential differ-
ences in allelic distribution due to heterogeneous racial
admixture. We adopted the classification scheme used
in the 2000 Brazilian Census [17], which relies on self-
perception of skin color. Accordingly, the individuals
were distributed into the following three color groups:
white, black and intermediate. The term “color” (cor in
Portuguese) is preferred to “race” in Brazil because it
captures the continuous aspects of phenotypes and also
because a racial descent rule is not operational in this
country [18]. The color stratification was not intended
as an accurate ethnic classification. Instead, our objec-
tive was to evaluate potential differences in the fre-
quency distribution of PTGS2 SNPs to ascertain if an
independent population control would be necessary in
the case-control study.
The second step was a case-control study, designed to
evaluate the genotype-associated risk of breast cancer
for the most prevalent PTGS2 SNPs, i.e., those with at
least 0.10 MAF. This case-control study involved 318
women with breast cancer and 273 healthy controls.
The patients had a confirmed diagnosis of breast cancer
based on histopathological evaluation and were under
current treatment at the Brazilian National Cancer Insti-
tute. The patients were assigned a recruitment interview
when scheduled for routine blood exams. The controls
were non-related healthy women with no signs or symp-
toms of breast cancer who were recruited among
patients’ escorts, hospital staff and blood donors of the
Brazilian National Cancer Institute. The recruitment of
both patients and controls occurred between January
and October 2008.
All volunteers were informed about the procedures of
the study and gave written consent to participate.
Patients and controls were interviewed by trained per-
sonnel using a questionnaire to determine demographic
and lifestyle characteristics. Information on clinical his-
tory was obtained from medical records for patients
(N = 250) and collected in an additional questionnaire
for controls (N = 183). The study was approved by the
Ethics Committee of the Brazilian National Cancer Insti-
tute (Protocol #116/07).
SNP Screening and Genotyping
Peripheral blood samples (3 mL) were collected from all
subjects (volunteers, cases and controls). DNA was
extracted using the DNAzol system (Invitrogen Life
Technologies, Carlsbad, USA), following the procedures
recommended by the manufacturer and were used to
search for SNPs of the PTGS2 gene (GenBank accession
#AY382629). The blood samples were kept at 4°C until
DNA extraction, which was performed within 24 h of
blood collection.
The genotyping analyses were performed by denatur-
ing high-performance liquid chromatography (dHPLC),
using the Wave™ DNA Fragment Analysis System
(Transgenomic, Omaha, NE) or by PCR-RFLP (all
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marizes the PCR conditions, the sets of primers and the
enzymes used for each analysis.
In the case of dHPLC analysis, all samples with chro-
matographic profiles suggestive of variation in the gene
sequence were analyzed using ABI PRISM-377 equip-
ment (TaqMan, PE Biosystems, Foster City, CA, USA).
A portion of controls (10% of the samples) was also ana-
lyzed by automatic sequencing, and the results matched
completely.
The four SNPs selected for the case-control study
were genotyped with the same sets of primers used in
the screening step. The SNPs rs689465, rs689466 and
rs20417 could not be identified by dHPLC and were
genotyped by PCR-RFLP (Table 1).
Statistical Analysis
Allelic and genotypic frequencies were derived by gene
counting and the adherence to the Hardy-Weinberg prin-
ciple was evaluated by the chi-square test for goodness-
of-fit. The evaluation of pairwise linkage disequilibrium
was performed using the Fisher exact test, available on-
line in GENEPOP (http://genepop.curtin.edu.au/; [19]),
whereas the haplotype patterns were inferred using Hap-
loview (http://www.broadinstitute.org/haploview;[20]),
based on the algorithm of expectation and maximization.
Comparisons of demographic and clinical features and of
genotypic and haplotypic distributions between patients
and controls were performed using the chi-square test
for proportions. Univariate logistic regression analyses
were performed to identify independent factors influen-
cing the risk of developing breast cancer, which was esti-
mated by the odds ratio (OR) with 95% confidence
interval (95% CI). The threshold for significance was set
at P < 0.05 (Pearson P-value). The clinically relevant fac-
tors with independent effects on breast cancer risk (OR
a n d9 5 %C I> 1 )w e r eu s e dt oc r e a t eam u l t i v a r i a t ef i n a l
model using the Enter method. All statistical analyses
were conducted using SPSS 13.0 for Windows (SPSS Inc.,
Chicago, Illinois).
Results
The screening analysis of the PR and 3’-UTR of the
PTGS2 gene in 67 healthy Brazilians revealed the exis-
tence of nine SNPs, which occurred with the following
MAFs: -1290AG (rs689465, 0.22); -1195AG (rs689466,
0.15); -1131GA (rs20415, 0.007); -765GC (rs20417, 0.32),
-604TC (rs20419, 0.015), -163CG (rs5270, 0.02), -62CG
(rs20424, 0.007), 8473TC (rs5275; 0.22) and 9850AG
(rs4648298; 0.01). The SNP 10335GA (rs689469), which
was reported to have a MAF of 0.02 among the Spanish
[16], was not found.
The SNPs rs689465, rs689466, rs20417 and rs5275,
which showed a higher than 0.10 MAF in this first
Table 1 Nucleotide PRIMER sequences and PCR conditions for genotyping by dHPLC or PCR-RFLP
PRIMER Name Nucleotide sequence Region Identified SNP Number of cycles Melting Temperature Enzyme
#
-1290AG F5 ’ TGCTGTCATTTTCCTGTAATGC 3’ PR rs689465 34 60°C PciI
-1195AG R5 ’ TTTCTCTCCCTGATGCGTGG 3’ rs689466 AluI
AM1* F5 ’ GCTGTCAAAATCTCCCTTCC 3’ PR rs20415 30 58°C
R5 ’ CCACGCATCAGGGAGAGAAA 3’
AM2* F5 ’ AACCAAAATAATCCACGC 3’ PR 30 63°C
R5 ’ CAAGGAGGGGGTGAAG 3’
-765GC F5 ’ CTTTGTCCATCAGAAGGCAGG 3’ PR rs20417 35 63°C AciI
R5 ’ TAGAGGGTCGAGGAAGTCACG 3’
AM3* F5 ’ TTACCTTTCCCGCCTCTC 3’ PR rs20419 30 58°C
R5 ’ GCGTCGTCACTAAAACATAAAAC 3’
AM4* F5 ’ GCTATGTATGTATGTGCTGC 3’ PR 31 55°C
R5 ’ GAACTGGCTCTCGGAAGC 3’
AM5* F5 ’ CGGTATCCCATCCAAGGC 3’ PR rs5270 31 55°C
R5 ’ CAGTGAGCGTCAGGAGCA 3’ rs20424
8473TC F5 ’ CTGTTGCGGAGAAAGGAGTC 3’ 3’-UTR rs5275 30 58°C
R5 ’ TCAAACAAGCTTTTACAGGTGA 3’
9850AG** F5 ’ CGTTCCCATTCTAATTAATGCCCTT 3’ 3’-UTR rs4648298 34 50°C AluI
R5 ’ TGTGTCAAGCACTGTGGGTTTTAAT 3’
10335GA F5 ’ TTTGGGAAGAGGGAGAAAATGA 3’ 3’-UTR rs689469 30 56°C
R5 ’ TATGCGAATGTTTCAGTGCC 3’
* 15; ** 16; PR: Promoter Region; 3’-UTR: 3’;Untranslated Region
# Enzymes used for PCR-RFLP. All other analyses were performed by dHPLC.
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zation in a larger sample (Table 2). No differences were
observed in the allelic frequencies due to gender or skin
color for any of the SNPs studied. All genotypic distri-
butions followed Hardy-Weinberg equilibrium. Our
results indicate strong pairwise linkage disequilibrium
involving SNPs rs689465, rs20417 and rs5275 in the
three possible combinations (Table 3). In fact, the minor
alleles of these three SNPs often occurred simulta-
neously, whereas the rs689466 G allele occurred mostly
as an isolated variation.
The next step was a case-control study, conducted to
examine the association between SNPs rs689465,
rs689466, rs20417 and rs5275 and the occurrence of
breast cancer. Cases and controls were first compared
with regard to the distribution profile of clinical aspects
potentially implicated in the risk of developing cancer
and that could interfere as confounding factors on the
analysis of the risk associated to PTGS2 SNPs (Table 4).
A significant difference between cases and controls was
found only for age (OR = 1.72, 95% CI = 1.24-2.39; P =
0.001).
The genotypic distributions of PTGS2 SNPs in cases
and controls are shown in Table 5. Our results indicate
a significant difference in the distribution of rs5275 gen-
otypes, with a higher frequency of heterozygotes among
cases than among controls (OR = 1.44, 95% CI = 1.01-
2.06; P = 0.043). To control possible confounding vari-
ables that may have influenced the observed association
measures, a multivariate regression model was built.
The best model, combining the effects of age and the
rs5275 SNP, showed a higher risk for rs5275 heterozy-
gotes (ORadjusted = 1.43, 95% CI = 1.00-2.06; P = 0.049).
The analysis of rs5275 SNP under recessive or dominant
models did not confirm the risk association for breast
cancer (data not shown).
The distribution of PTGS2 haplotypes among cases
and controls was also examined (Table 6). All genotype
information was included in the analysis, and the haplo-
type inference could be obtained for 302 cases and 264
controls. No significant difference in the haplotypic dis-
tribution was observed between patients and controls (P
= 0.99, Fisher exact method). The three less frequent
haplotypes appeared to be differently expressed between
cases and controls. However, it was not possible to cal-
culate the OR between cases and controls due to the
absence of these haplotypes in one of the groups. An
adequate evaluation of their impact on cancer risk
would require a much larger sample. To further evaluate
the impact of the rs5275 SNP on the risk of developing
Table 2 Minor allelic frequency (MAF) of PTGS2 SNPs
in Brazilians
SNP Population Alleles (N) MAF (95%CI) P c2
rs689465 AG rs689465 G
Total * 710 0.17 (0.14-0.20)
Men 222 0.20 (0.15-0.25) 0.273
Women 488 0.16 (0.13-0.19)
Whites 298 0.18 (0.14-0.22) 0.87
Intermediates 248 0.16 (0.11-0.20)
Blacks 164 0.16 (0.11-0.22)
rs689466 AG rs689466 G
Total * 710 0.13 (0.10-0.15)
Men 220 0.16 (0.12-0.21) 0.221
Women 490 0.12 (0.09-0.15)
Whites 298 0.12 (0.08-0.16) 0.728
Intermediates 246 0.13 (0.09-0.17)
Blacks 166 0.15 (0.10-0.21)
rs20417 GC rs20417 C
Total * 772 0.30 (0.27-0.33)
Men 242 0.28 (0.26-0.38) 0.783
Women 528 0.29 (0.25-0.33)
Whites 328 0.30 (0.25-0.35) 0.949
Intermediates 276 0.29 (0.23-0.34)
Blacks 168 0.31 (0.24-0.38))
rs5275 TC rs5275 C
Total * 698 0.30 (0.26-0.33)
Men 208 0.29 (0.23-0.35) 0.882
Women 490 0.30 (0.26-0.34)
Whites 296 0.27 (0.22-0.32) 0.53
Intermediates 250 0.31 (0.25-0.36)
Blacks 154 0.34 (0.26-0.41)
* Differences in values are due to missing data (no PCR amplification).
P c2: Chi-square test (Pearson P-value); 95%CI: 95% Confidence Interval
Table 3 Pairwise linkage disequilibrium between PTGS2
SNPs in Brazilians
SNP c2 P (Fisher) [D’]* R2**
rs689465 & rs689466 3.159 0.206 99 4
rs689465 & rs20417 infinity <0.0001 77 31
rs689466 & rs20417 6.860 0.032 62 3
rs689465 & rs5275 infinity <0.0001 51 13
rs689466 & rs5275 1.095 0.579 49 2
rs20417 & rs5275 infinity <0.0001 44 18
*D ’ (degree of imbalance) in module; ** R2 (degree of correlation).
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according to the presence of the rs5275 T or C allele.
No risk association was found for rs5275 C-containing
haplotypes when considered as a combined group (OR
= 1.09, 95% CI = 0.83-1.43; P = 0.5). Taken together,
the results appear to indicate no association between
PTGS2 SNPs (in their most frequent haplotypes) and
the risk of breast cancer.
Discussion
In the past five years, several studies have aimed to evalu-
ate the impact of PTGS2 SNPs on the risk of developing
different types of cancer [10,15,16,21-46]. However, most
of these studies evaluated only one or a few SNPs at a
time, sometimes with no clear selection criteria. Zhang
et al. [10] were the first to perform a screening strategy to
identify the most frequent PTGS2 SNPs. This approach
was also preferred in our case, due to the heterogeneity of
the Brazilian population and to the consequent hazards of
using frequency data obtained elsewhere.
In our screening strategy, we evaluated 1.5 kb of the
PR and 1.2 kb of the 3’-UTR, which encompass the
most important regulatory sites of PTGS2 expression
[9,10,13]. The focus on the regulatory regions of the
Table 4 Impact of clinical and demographic characteristics on the risk of breast cancer in Brazilian women
Characteristic Category Cases Controls OR 95%CI P c2
Age* (years) < 48 147 163 1
≥ 48 171 110 1.72 (1.24-2.39) 0.001
Missing data 0 0
Menarche (Age) < 12 120 93 1
≥ 12 120 74 1.25 (0.84-1.86) 0.258
Missing data 78 106
Menopause (Age)** ≤ 54 98 62 1
≥ 55 10 5 0.79 (0.25-2.42) 0.68
Missing data 127 103
First Birth (Age) ≤ 30 161 103 1
≥ 31 or nulliparous 75 68 1.41 (0.93-2.13) 0.09
Missing data 82 102
Fertile Time¥ <3 5 4 5 3 5 1
≥ 35 60 27 1.73 (0.83-3.42) 0.089
Missing data 3 5
Use of contraceptives † < 2 110 105 1
≥2 92 59 1.49 (0.97-2.27) 0.065
Missing data 116 109
Use of HRT
θ no 79 43 1
yes 25 20 0.68 (0.32-1.44) 0.276
Missing data 4 4
Use of NSAIDs no 187 154 1
yes 31 13 1.96 (0.99-3.88) 0.053
Missing data 100 106
BMI Underweight: ≤ 18.4 9 1 4.13 (0.50-33.6) 0.28
Normal: 18.5 - 24.9 98 45 1
Overweight: ≥ 25.0 159 63 1.15 (0.73-1.83) 0.55
Missing Data 52 164
Smoking Habit no 174 83 1
yes 98 38 1.23 (0.77-1.94) 0.42
Missing data 46 152
Color White 131 120 0.619‡
Intermediate 125 96
Black 62 57
Missing data 0 0
* 48 years old is the median of cases + controls; ** Menopausal status: postmenopausal: cases n = 108, controls: n = 67; premenopausal: cases: n = 83, controls n
= 103; ¥ Age of Menopause - Age of Menarche (only for women in menopause); † For at least 2 years;
θHRT: Hormonal Reposition Therapy (only for women in
menopause); NSAIDs: Non-Steroidal Anti-Inflammatory Drugs; BMI: Body Mass Index at diagnosis (patients) or at recruitment (controls), BMI = weight (Kg)/height
2
(m
2); OR: Odds Ratio; 95%CI: 95% Confidence Interval; P from Chi-square test (Pearson p-value); ‡ P from Fisher test.
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unstable [13], and an increase in its stability promotes
COX-2 expression in colon cancer cells [13]. In addi-
tion, in vitro studies indicate possible functional effects
of the SNPs rs689466 and rs20417 on PTGS2 promoter
activity (evaluated by a luciferase gene reporter system)
[9,10] and on COX-2 activity (evaluated by PGE2 pro-
duction in human monocytes) [47]. Although screening
the entire PTGS2 gene would be theoretically preferable
because variants in the coding and non-coding regions
could tag other functional SNPs, previous reports
involving these variants suggest no significant
effect on COX-2 activity [48] or on cancer risk
[16,21,25,28-30,32,33,35-43,45,46]. The only exception is
a recent publication by Zhao et al. [49], which suggests
an increased risk of esophageal squamous cancer asso-
ciated to SNP rs20432 that is located in intron 5. This
positive association, however, is not confirmed in other
types of cancer [16,21,25,29,33,36,45].
In our screening analysis, we found nine SNPs, five of
which showed very low MAFs (approximately 0.01):
rs20415, rs20419, rs5270, rs20424 and rs4648298. These
MAFs are in accordance with previous reports involving
different populations [15,16,50]. The SNPs rs689465,
rs689466, rs20417 and rs5275 were selected for the
case-control study and appear to be the most frequent
SNPs in other Western populations [16,21,23,25,51-58].
The present work is the first study on the frequency of
PTGS2 SNPs among Brazilians, who are one of the
world’s most heterogeneous populations as a result of
extensive interethnic crosses over the last 500 years
between autochthonous Amerindians, European coloni-
zers and Africans [59-61]. Studies based on population-
specific alleles, blood groups and electrophoresis of pro-
tein markers have outlined the hazards of equating color
or race with geographic ancestry in Brazilians [18,59-63].
Thus, the stratification of our population into three
groups based on self-reported skin color (white, inter-
mediate and black) was not intended for ethnic classifica-
tion but to evaluate potential differences in the frequency
of PTGS2 SNPs due to heterogeneous racial admixture.
Because no significant difference in the genotype distri-
bution was detected for the four SNPs among the color
groups, either in the general population or among
patients (data not shown), no population control or stra-
tification based on continental-specific alleles was neces-
sary in the case-control study.
In the present study, there was no association between
rs689465, rs689466 or rs20417 and the occurrence of
breast cancer. The results for rs689466 and rs20417 are
in accordance with previously published data [23,25,39].
This is the first report on rs689465 and the risk of
breast cancer.
Our results show an increase in the frequency of
rs5275 TC heterozygotes among patients compared to
controls, with an apparent increased risk of breast
Table 5 Genotypic distribution of PTGS2 SNPs in
cases and controls
SNP Population N* Genotypic Distribution N (Freq) P c2
rs689465 AA AG GG
Cases 290 202 (0.69) 83 (0.28) 5 (0.03) 0.927
Controls 244 172 (0.70) 67 (0.27) 5 (0.03)
rs689466 AA AG GG
Cases 289 224 (0.77) 62 (0.21) 3 (0.02) 0.968
Controls 245 190 (0.77) 51 (0.21) 3 (0.02)
rs20417 GG GC CC
Cases 308 157 (0.51) 127 (0.41) 24 (0.08) 0.731
Controls 264 129 (0.49) 117 (0.44) 18 (0.07)
rs5275 TT TC CC
Cases 294 125 (0.42) 149 (0.51) 20 (0.07) 0.046
Controls 244 120 (0.49) 99 (0.41) 25 (0.10)
N: Number of examined samples (with available PCR amplification);
* Differences in sample sizes for cases and controls are due to available data
in each category. Freq: Frequency; P c2: P from Chi-square test (Pearson p-
value).
Table 6 Haplotype distribution in patients and controls
and association with breast cancer risk
Cases Controls
Haplotype N F N F OR 95%CI P c2
AAGT 284 0.47 248 0.47 1
1 AAGC 72 0.12 63 0.12 0.99 0.68-1.45 0.92
GACC 60 0.1 48 0.09 1.09 0.72-1.62 0.68
AACC 54 0.09 42 0.08 1.12 0.72-1.73 0.65
GAGC 6 0.01 0 0 0.03*
Total 192 0.32 153 0.29 1.09 0.83-1.43 0.5
2 AGGT 66 0.11 53 0.1 1.08 0.72-1.62 0.68
AACT 30 0.05 26 0.05 1.00 0.58-1.75 1
GACT 24 0.04 26 0.05 0.80 0.45-1.44 0.46
AGCT 0 0 5 0.01 0.02*
GAGT 0 0 5 0.01 0.02*
Others 8 0.01 12 0.02 0.58 0.23-1.44 0.23
Total 128 0.21 127 0.24 0.88 0.65-1.18 0.4
Total 604 1 528 1
The haplotype combining the predominant alleles was used as a reference.
Group 1 was formed by any haplotype containing the rs5275 C allele and
group 2 included all the other haplotypes. The haplotypes with less than 1%
frequency (Others) are not listed. The impact on breast cancer risk was
calculated for the two groups, considering the Odds Ratio (OR) and the 95%
Confidence Interval (95%CI) P: Pearson P-value; N: Number of haplotypes. F:
Frequency of haplotypes. * Fisher Exact Probability Test (two-tailed). OR was
not calculated because of N = 0.
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The borderline significance of this association, however,
limits its confidence. The number of subjects in our
case-control study was initially calculated considering
the allele frequencies in the general population and a
possible 2-fold increase in the rs5275 MAF among
patients, with a significance level of 5% and an error
level of 20%. Although the actual sample size was larger
than first estimated to ensure statistical power, it was
still small for the evaluation of inheritance models or
for the study of the less frequent haplotypes.
A review of the literature concerning the impact of
rs5275 on the risk of breast cancer shows conflicting
results. Langsenlehner et al. [24] found that carriers of
the rs5275 C allele in the Austrian population were
more frequent among breast cancer patients (34.8%)
than among age-matched controls (29.9%; P = 0.018),
with an increased risk of breast cancer in rs5275CC
homozygotes (OR = 2.1; 95% CI = 1.3-3.3; P = 0.002).
These results, however, were not corroborated by other
authors. Vogel et al. [34] found no association between
rs5275 genotype and breast cancer susceptibility, which
was confirmed in three independent large studies
[25,28,39]. Cox et al. [25], combining data from three
separate studies in the American population (N = 5144),
indicated that women homozygous for the rs5275 C
allele have a 20% lower risk of breast cancer than those
homozygous for the T allele (OR = 0.80, 95% CI = 0.66-
0.97) [25]. This reduced risk was confirmed by Zhu
et al. [64] in a meta-analysis, which, however, did not
include the large number of individuals in the work by
Abraham et al. [28] and by Dossus et al. [39]. Taken
together, these studies appear to suggest no strong influ-
ence of rs5275 SNP on breast cancer risk.
The present work indicates that variants in the PR
and in the 3’ UTR of PTGS2 do not appear to greatly
influence breast cancer risk, as the apparent risk asso-
ciation found for rs5275 SNP was limited to heterozy-
gotes with a low OR value and borderline significance.
However, the apparently negative results do not
exclude potential low risks (i.e., OR < 1.5), whose
detection with high level of statistical significance (P <
0.001) would require large individual studies or meta-
analysis (N > 6000). Our data also highlight the exis-
tence of various PTGS2 haplotypes that have not been
thoroughly studied and should be considered for
further evaluation of risk association with cancer
development and/or progression.
Conclusion
Our results indicate no strong association between the
four most frequent PTGS2 SNPs and the risk of breast
cancer.
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